Juul is planning to cut 650 jobs, or 16% of its total workforce. The company is looking to eliminate nearly $1 billion in costs next year. Juul is also planning to trim marketing spending and instead focus on direct marketing to smokers. (CNBC)

Amarin’s fish oil pill Vascepa has received positive reviews from the Food and Drug Administration. Some experts said Amarin’s choice of placebo in last year’s clinical trial for Vascepa may have affected its positive results, but an FDA panel said its tests were inconclusive. (Reuters)

Small biotechs are worrying that they could be hit hardest by Speaker of the House Nancy Pelosi’s drug price bill. These companies are concerned that venture capital money would leave the industry if the bill passes and frustrated about being left out of the drug price debate in Washington. (STAT)

Celgene has inked its second deal with Skyhawk, worth $92 million. The pact will add oncology, immuno-oncology and autoimmune diseases targets to Celgene, beefing up areas where the company and soon-to-be-owner Bristol-Myers Squibb want to focus. (Endpoints)

There were 11 newly reported measles cases in the past month. That brings the total number of U.S. cases this year to 1,261, the worst outbreak since 1992, according to the Centers for Disease Control and Prevention. (Reuters)